SMO and skin basal cell carcinoma: Consequently, a number of Hh-pathway-targeting drugs are currently approved for clinical use in oncology including SMO inhibitors sonidegib and vismodegib (for use in BCC) and glasdegib (for use in acute myeloid leukemia) [34–36].